Jpmorgan Chase & CO Athira Pharma, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATHA
# of Institutions
66Shares Held
16.9MCall Options Held
112KPut Options Held
68K-
Perceptive Advisors LLC New York, NY5.4MShares$3.4 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$1.02 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$940,4580.39% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$940,4580.04% of portfolio
-
Black Rock Inc. New York, NY676KShares$426,0330.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $23.8M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...